Company: ANTX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001193125-25-277673
Chunk: 10

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 6
Chunk 10
---
(a)Exhibits. 

The exhibits listed below are filed as part of this Quarterly Report on Form 10-Q.

     Incorporated by Reference

     ExhibitNumber
      
     Description
      
     Form
      
     File No.
      
     Exhibit
      
     Filing Date

     3.1
      
     Amended and Restated Certificate of Incorporation.
      
     8-K
      
     001-41331
      
     3.1
      
     June 24, 2024

     3.2
      
     Amended and Restated Bylaws.
      
     S-1
      
     333-263295
      
     3.4
      
     March 4, 2022

     3.3
      
     Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on August 15, 2024.
      
     8-K
      
     001-41331
      
     3.1
      
     August 19, 2024

     4.1
      
     Form of Pre-Funded Warrant
      
     8-K
      
     001-41331
      
     4.1
      
     June 20, 2025

     31.1*
      
     Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     31.2*
      
     Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     32.1*†
      
     Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     32.2*†
      
     Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350